UK secures early access to 90m doses of ‘promising’ COVID-19 vaccine candidate

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising COVID-19 vaccine candidates.

Announced by Business Secretary Alok Sharma today (Monday 20 July), the Government has agreed significant partnerships with leading pharmaceutical and vaccine companies BioNTech/Pfizer and Valneva that are developing innovative new vaccines to protect people against COVID-19.

The Government has also secured access to treatments containing COVID-19-neutralising antibodies from AstraZeneca to protect those who cannot receive vaccines such as cancer and immunocompromised patients.

As a result of these partnerships, England, Scotland, Wales and Northern Ireland could have access to enough doses to vaccinate and protect priority groups identified, such as frontline health and social care workers and those at increased health risk.

With today’s announcement, the Government has now secured access to three different types of COVID-19 vaccines that are being developed here and around the world, giving the UK the most likely chance of getting access to a safe and effective vaccine at the quickest speed.

The Government has also today launched the NHS COVID-19 vaccine research registry. This new website will enable people in the UK to play their part by volunteering for future vaccine studies.

The new online service will allow members of the public to register their interest and be contacted to participate in clinical studies. To enable large-scale vaccine studies to take place across the UK, the aim is to get 500,000 people signed up by October, which is considered vital in the fight against coronavirus.

Clinical studies with hundreds of thousands of volunteers will help scientists and researchers better understand the effectiveness of each vaccine candidate and will considerably speed up efforts to discover a safe and workable vaccine.

“The hunt to find a vaccine is a truly global endeavour and we are doing everything we can to ensure the British public get access to a safe and effective coronavirus vaccine as soon as possible,” said Business Secretary Alok Sharma.

“This new partnership with some of the world’s foremost pharmaceutical and vaccine companies will ensure the UK has the best chance possible of securing a vaccine that protects those most at risk.

“The public can also play their part in vaccine research through the new NHS vaccine research register. By signing up and participating in important clinical studies, together we can speed up the search for a vaccine and end the pandemic sooner.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...